| Over a week ago | ||||
JPMorgan analyst Richard… JPMorgan analyst Richard Vosser upgraded Lonza to Overweight from Neutral with a price target of CHF 680, up from CHF 600. Potential for capital deployment to boost the company's biologic fill finish capabilities over the next 12 months and one of the strongest topline growth stories in the space should drive share outperformance, Vosser tells investors in a research note. | ||||
Deutsche Bank analyst… Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Lonza to CHF 680 from CHF 630 and keeps a Buy rating on the shares. | ||||
Berenberg analyst Xian… Berenberg analyst Xian Deng raised the firm's price target on Lonza to CHF 690 from CHF 410 and keeps a Buy rating on the shares. | ||||
Morgan Stanley analyst… Morgan Stanley analyst James Quigley raised the firm's price target on Lonza to CHF 645 from CHF 630 and keeps an Overweight rating on the shares. | ||||
| Over a month ago | ||||
Capricor Therapeutics… Capricor Therapeutics (CAPR) and Lonza (LZAGY) announced that the companies have entered into an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells technology for the treatment of Duchenne Muscular Dystrophy and complications arising from COVID-19. CAP-1002 completed the positive HOPE-2 phase 2 clinical trial and has been granted orphan drug designation by the FDA for the treatment of DMD. CAP-1002 also received FDA acceptance of its IND application for a phase 2 clinical trial of CAP-1002 in patients with COVID-19 in August 2020, as announced by Capricor. The agreement aims to expand Capricor's manufacturing capacity for potential late-stage clinical trials and commercialization. Operations will begin with a tech-transfer to Lonza's Houston center of excellence, where Lonza will perform process development activities for late-clinical and commercial-scale GMP manufacturing of CAP-1002. | ||||
Morgan Stanley analyst… Morgan Stanley analyst James Quigley lowered the firm's price target on Lonza to CHF 630 from CHF 640 and keeps an Overweight rating on the shares. | |
Arbor Biotechnologies and… Arbor Biotechnologies and Lonza announced a license agreement to provide Lonza with access to Arbor's next-generation CRISPR-based gene editing technology. Lonza will have the ability to utilize Arbor's proprietary technology in its bioproduction products and services. The financial details of this agreement were not disclosed. |
| Over a quarter ago | ||||
UBS analyst Patrick… UBS analyst Patrick Rafaisz raised the firm's price target on Lonza to CHF 610 from CHF 520 and keeps a Neutral rating on the shares. | ||||
KeyBanc analyst Paul… KeyBanc analyst Paul Knight initiated coverage of Lonza with a Sector Weight rating and CHF 635 price target. The analyst said that the sales of the company's Specialty Chemicals unit in fiscal 2021 will reduce EBITDA and create difficult comparisons, but biologics can drive growth to 10% or higher. | ||||
Societe Generale analyst… Societe Generale analyst Justin Smith raised the firm's price target on Lonza to CHF 705 from CHF 655 and keeps a Buy rating on the shares. | ||||